Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Astellas Gene Therapies, Inc. is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals sector. These matters are distributed among 2 distinct examiners and 2 distinct art units. VIJAYARAGHAVAN, JAGAMYA NMN is the busiest examiner, handling 2 pending office actions. This concentration means one individual is responsible for the majority of the company's current pending workload.
The presence of 2 distinct art units indicates the gene therapy applications are being reviewed by different specialized groups. Practitioners should focus on the preferences of VIJAYARAGHAVAN, JAGAMYA NMN, as that individual oversees the majority of the 3 pending office actions. With multiple examiners involved, the applicant must still account for different examination styles. However, the concentration under the busiest examiner simplifies the coordination of the portfolio. This biotechnology focus across the 2 distinct art units suggests a specialized but slightly varied technical range. Managing these separate examiner relationships requires a flexible approach to prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 2 | 62.5% | +49.3% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | POPA, ILEANA | — |
| 18039813 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING CAG REPEAT DISEASES | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | POPA, ILEANA | — | §103 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18039813 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING CAG REPEAT DISEASES | VIJAYARAGHAVAN, JAGAMYA NMN | 1637 | §103§112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | 31d overdue | Pending | Jun 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial